ATL15 Antibody

Contextual Clarification of Terminology

The term "ATL15" appears in two distinct contexts across the search results, neither of which refers to an antibody:

a. Patient Identifier in Clinical Studies

Source lists "ATL15" as a patient identifier in a gene expression profiling study of adult T-cell leukemia/lymphoma (ATL). For example:

This designation follows a numbering system for anonymized patient data, not an antibody.

b. Aspirin-Triggered Lipoxin (ATL) Analog

Source references "ATL 15-epi-lipoxin A4," a lipid mediator derived from aspirin-triggered biochemical pathways. This compound modulates immune responses but is unrelated to antibodies .

Antibody Research in ATL

While no "ATL15 Antibody" exists, antibodies play critical roles in ATL research and therapy:

a. Anti-CCR4 Antibodies

• Mogamulizumab, a defucosylated anti-CCR4 monoclonal antibody, is FDA-approved for ATL. It targets CCR4-positive malignant T cells, achieving a 50% response rate in relapsed/refractory ATL .

• Mechanism: Depletes regulatory T cells (Tregs) via antibody-dependent cellular cytotoxicity (ADCC) .

b. Antibody-Drug Conjugates (ADCs)

• Brentuximab vedotin (anti-CD30 ADC) and other ADCs are under investigation for ATL, leveraging antibodies to deliver cytotoxic payloads .

Common Misinterpretations

The confusion may stem from:

• Naming Conventions: "ATL15" in source refers to a patient, not an antibody.

• Abbreviation Overlap: "ATL" is standard for adult T-cell leukemia/lymphoma, not a compound prefix.

Recommendations for Further Inquiry

To resolve ambiguities:

1. Verify the correct nomenclature (e.g., whether "ATL15" refers to a gene, protein, or clinical trial code).

2. Explore antibodies targeting ATL-associated antigens (e.g., CD25, CD30, CCR4) documented in sources .